ATE180832T1 - Funktionelle rolle von adrenomedullin(am) und dem gen-verwandten produkt(pamp) in der menschlichen pathologie und physiologie - Google Patents
Funktionelle rolle von adrenomedullin(am) und dem gen-verwandten produkt(pamp) in der menschlichen pathologie und physiologieInfo
- Publication number
- ATE180832T1 ATE180832T1 AT96928205T AT96928205T ATE180832T1 AT E180832 T1 ATE180832 T1 AT E180832T1 AT 96928205 T AT96928205 T AT 96928205T AT 96928205 T AT96928205 T AT 96928205T AT E180832 T1 ATE180832 T1 AT E180832T1
- Authority
- AT
- Austria
- Prior art keywords
- present
- methods
- adrenomedullin
- physiology
- peptides
- Prior art date
Links
- 102000004379 Adrenomedullin Human genes 0.000 title abstract 10
- 101800004616 Adrenomedullin Proteins 0.000 title abstract 10
- ULCUCJFASIJEOE-NPECTJMMSA-N adrenomedullin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)NCC(=O)N[C@@H]1C(N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CSSC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)[C@@H](C)O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 ULCUCJFASIJEOE-NPECTJMMSA-N 0.000 title abstract 8
- 230000035479 physiological effects, processes and functions Effects 0.000 title abstract 2
- 102400001018 Proadrenomedullin N-20 terminal peptide Human genes 0.000 title 1
- 101800000795 Proadrenomedullin N-20 terminal peptide Proteins 0.000 title 1
- PIRWNASAJNPKHT-SHZATDIYSA-N pamp Chemical compound C([C@@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)N)C(C)C)C1=CC=CC=C1 PIRWNASAJNPKHT-SHZATDIYSA-N 0.000 title 1
- 230000007170 pathology Effects 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
- 238000000034 method Methods 0.000 abstract 5
- 230000003914 insulin secretion Effects 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 230000003305 autocrine Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 230000006806 disease prevention Effects 0.000 abstract 1
- 231100000673 dose–response relationship Toxicity 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000003102 growth factor Substances 0.000 abstract 1
- 230000001613 neoplastic effect Effects 0.000 abstract 1
- 230000000144 pharmacologic effect Effects 0.000 abstract 1
- 230000035755 proliferation Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- Communicable Diseases (AREA)
- Neurosurgery (AREA)
- Toxicology (AREA)
- Physical Education & Sports Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Zoology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US251495P | 1995-08-18 | 1995-08-18 | |
| US293695P | 1995-08-30 | 1995-08-30 | |
| US1317296P | 1996-03-12 | 1996-03-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE180832T1 true ATE180832T1 (de) | 1999-06-15 |
Family
ID=27357180
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT96928205T ATE180832T1 (de) | 1995-08-18 | 1996-08-16 | Funktionelle rolle von adrenomedullin(am) und dem gen-verwandten produkt(pamp) in der menschlichen pathologie und physiologie |
Country Status (7)
| Country | Link |
|---|---|
| US (4) | US6320022B1 (enExample) |
| EP (1) | EP0845036B1 (enExample) |
| JP (2) | JPH11512087A (enExample) |
| AT (1) | ATE180832T1 (enExample) |
| CA (1) | CA2229741C (enExample) |
| DE (1) | DE69602756T2 (enExample) |
| WO (1) | WO1997007214A1 (enExample) |
Families Citing this family (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6440421B1 (en) | 1996-04-18 | 2002-08-27 | Auchkland Uniservices Limited | Treatment of bone disorders with adrenomedullin or adrenomedullin agonists |
| US5888963A (en) * | 1996-04-18 | 1999-03-30 | Auckland Uniservices Limited | Treatment of bone disorders with adrenomedullin |
| AU9369098A (en) * | 1997-09-26 | 1999-04-23 | Auckland Uniservices Limited | Therapeutic method |
| AU774725B2 (en) * | 1999-09-10 | 2004-07-08 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Determination of adrenomedullin-binding proteins |
| US20040047988A1 (en) * | 2000-11-17 | 2004-03-11 | Jin-Kyu Lee | Poly(methylsilsesquioxane) copolymers and preparation method thereof |
| FR2821080B1 (fr) * | 2001-02-20 | 2003-12-19 | Sanofi Synthelabo | Anticorps specifique de l'adrenomedulline humaine, composition pharmaceutique le contenant, ses applications therapeutiques |
| US20110087312A1 (en) * | 2001-03-02 | 2011-04-14 | Erchonia Corporatin | Method for Treatment of Diabetes and Prediabetes with Low-Level Laser Therapy |
| EP1372717A2 (en) | 2001-03-23 | 2004-01-02 | Aphton Corporation | Combination treatment of pancreatic cancer |
| US20090191232A1 (en) | 2001-05-04 | 2009-07-30 | Gevas Philip C | Combination therapy for the treatment of tumors |
| AU2003221096A1 (en) * | 2002-03-19 | 2003-09-29 | Oncorex, Inc. | Peptides, medicinal compositions containing the peptide and medicinal compositions for treating cancer |
| US20040127445A1 (en) * | 2002-08-28 | 2004-07-01 | Chondrogene Limited | Beta-2 microglobulin (B2M) and B2M related gene products for the regulation of osteoarthritis pathogenesis and chondrocyte proliferation |
| WO2004028352A2 (en) * | 2002-09-30 | 2004-04-08 | Bayer Pharmaceuticals Corporation | Methods for prediction and prognosis of cancer, and monitoring cancer therapy |
| JP2006517783A (ja) * | 2002-09-30 | 2006-08-03 | オンコセラピー・サイエンス株式会社 | ヒト骨髄性白血病に関連する遺伝子およびポリペプチド |
| WO2004032708A2 (en) * | 2002-10-04 | 2004-04-22 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Vasoregulating compounds and methods of their use |
| AU2003295422B2 (en) | 2002-11-07 | 2009-01-29 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | A new target for angiogenesis and anti-angiogenesis therapy |
| EP1608984A2 (en) | 2003-03-28 | 2005-12-28 | Aphton Corporation | Gastrin hormone immunoassays |
| US7228658B2 (en) | 2003-08-27 | 2007-06-12 | Weyerhaeuser Company | Method of attaching an end seal to manufactured seeds |
| CA2539467C (en) * | 2003-09-08 | 2012-11-13 | Frank Cuttitta | Non-peptide agonists and antagonists of adrenomedullin and gastric releasing peptide |
| US8691575B2 (en) * | 2003-09-30 | 2014-04-08 | Weyerhaeuser Nr Company | General method of classifying plant embryos using a generalized Lorenz-Bayes classifier |
| CA2486289C (en) * | 2003-11-25 | 2008-01-08 | Weyerhaeuser Company | Combination end seal and restraint |
| US20050108929A1 (en) * | 2003-11-25 | 2005-05-26 | Edwin Hirahara | Method and system for creating manufactured seeds |
| US20050108935A1 (en) * | 2003-11-25 | 2005-05-26 | Edwin Hirahara | Method and system of manufacturing artificial seed coats |
| CA2484533C (en) * | 2003-11-25 | 2008-12-02 | Weyerhaeuser Company | Systems and method of embryo delivery for manufactured seeds |
| US7555865B2 (en) * | 2003-11-25 | 2009-07-07 | Weyerhaeuser Nr Company | Method and system of manufacturing artificial seed coats |
| US7356965B2 (en) * | 2003-12-11 | 2008-04-15 | Weyerhaeuser Co. | Multi-embryo manufactured seed |
| US7591287B2 (en) * | 2003-12-18 | 2009-09-22 | Weyerhaeuser Nr Company | System and method for filling a seedcoat with a liquid to a selected level |
| US7568309B2 (en) * | 2004-06-30 | 2009-08-04 | Weyerhaeuser Nr Company | Method and system for producing manufactured seeds |
| US8158128B2 (en) | 2004-09-22 | 2012-04-17 | Cancer Advances, Inc. | Monoclonal antibodies to progastrin |
| CA2518279A1 (en) * | 2004-09-27 | 2006-03-27 | Weyerhaeuser Company | Manufactured seed having a live end seal coating |
| CA2518166C (en) * | 2004-09-27 | 2012-02-21 | Weyerhaeuser Company | Manufactured seed having a live end seal |
| US7547488B2 (en) * | 2004-12-15 | 2009-06-16 | Weyerhaeuser Nr Company | Oriented strand board panel having improved strand alignment and a method for making the same |
| US7654037B2 (en) * | 2005-06-30 | 2010-02-02 | Weyerhaeuser Nr Company | Method to improve plant somatic embryo germination from manufactured seed |
| US8168592B2 (en) | 2005-10-21 | 2012-05-01 | Amgen Inc. | CGRP peptide antagonists and conjugates |
| US8906857B2 (en) * | 2005-12-01 | 2014-12-09 | B.R.A.H.M.S. Gmbh | Methods for the diagnosis and treatment of critically ill patients with endothelin, endothelin agonists and adrenomedullin antagonists |
| US9829494B2 (en) * | 2005-12-01 | 2017-11-28 | Adrenomed Ag | Methods of treatment using ADM antibodies |
| DE102006052916A1 (de) * | 2006-11-08 | 2008-05-15 | Brahms Aktiengesellschaft | Diagnose und Risikostratifizierung von Diabetes mellitus mittels MR-proADM |
| EP2190533A2 (en) * | 2007-09-11 | 2010-06-02 | Mondobiotech Laboratories AG | Use of a peptide as a therapeutic agent |
| FR2934597B1 (fr) * | 2008-07-31 | 2013-04-19 | Univ Aix Marseille Ii | Anticorps se liant aux recepteurs de l'adrenomedulline et leurs utilisations comme medicament. |
| JP2012507021A (ja) * | 2008-10-31 | 2012-03-22 | ベー．エル．アー．ハー．エム．エス ゲゼルシャフト ミット ベシュレンクテル ハフツング | 心臓血管系に対する影響に関して食品及び／又は飲料及び／又は食事及び／又は栄養計画及び／又は薬剤を分類するための方法及びアッセイ |
| JP5843357B2 (ja) | 2009-02-03 | 2016-01-13 | アムニクス オペレーティング インコーポレイテッド | 延長組換えポリペプチドおよび延長組換えポリペプチドを含む組成物 |
| EP2389799A1 (en) * | 2010-05-25 | 2011-11-30 | BioMass Booster, S.L. | Method for increasing plant biomass |
| BR112012032406A2 (pt) * | 2010-06-18 | 2016-10-25 | Cezanne S A S | marcadores para o prognóstico e avaliação de risco de hipertensão induzida pela gravidez e pré-eclâmpsia |
| FR2964103B1 (fr) * | 2010-08-30 | 2018-11-23 | Universite D'aix-Marseille | Anticorps se liant a l'adrenomedulline et aux recepteurs de l'adrenomedulline et leurs utilisations comme medicament |
| JP5932279B2 (ja) * | 2011-10-07 | 2016-06-08 | ポーラ化成工業株式会社 | スクリーニング方法 |
| US8776012B2 (en) * | 2011-10-25 | 2014-07-08 | International Business Machines Corporation | Automatic scheduling of review meetings |
| EP4086283A1 (en) | 2011-11-16 | 2022-11-09 | AdrenoMed AG | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for prevention or reduction of organ dysfunction or organ failure in a patient having a chronic or acute disease or acute condition |
| HRP20190122T1 (hr) | 2011-11-16 | 2019-03-08 | Adrenomed Ag | Protutijelo protiv adrenomedulina (adm) ili fragment protutijela protiv adm ili okosnica ne-ig protiv adm, namijenjeni reguliranju ravnoteže tekućina kod pacijenta s kroničnom ili akutnom bolešću |
| EP2780370B1 (en) | 2011-11-16 | 2019-09-25 | AdrenoMed AG | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy of an acute disease or acute condition of a patient for stabilizing the circulation |
| MY178654A (en) * | 2011-11-16 | 2020-10-20 | Adrenomed Ag | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or an anti-adm non-ig protein scaffold for use in therapy |
| JP5953108B2 (ja) * | 2012-05-14 | 2016-07-20 | ポーラ化成工業株式会社 | スクリーニング方法 |
| US9486503B2 (en) * | 2012-10-04 | 2016-11-08 | Shionogi & Co., Ltd. | Medicinal agent for suppressing malignant tumor metastasis |
| JP6673847B2 (ja) * | 2013-12-20 | 2020-03-25 | アンギオビオメト ゲゼルシャフト ミット ベシュレンクテル ハフツング | 癌治療に使用するためのアドレノメデュリンバインダー |
| ES2754478T3 (es) * | 2015-03-12 | 2020-04-17 | Fund Rioja Salud | Uso de un inhibidor de la adrenomedulina para la fabricación de un medicamento útil en la prevención y tratamiento de enfermedades que reducen la densidad ósea |
| CA3064962A1 (en) | 2017-05-26 | 2018-11-29 | The Governors Of The University Of Alberta | Self-assembling peptide for activating human mast cells |
| WO2018232230A1 (en) | 2017-06-15 | 2018-12-20 | Cancer Advances Inc. | Compositions and methods for inducing humoral and cellular immunities against tumors and cancer |
| US12150978B2 (en) | 2017-06-15 | 2024-11-26 | Cancer Advances Inc. | Compositions and methods for preventing tumors and cancer |
| EP3438668A1 (en) * | 2017-08-04 | 2019-02-06 | B.R.A.H.M.S GmbH | Diagnosis and risk stratification of fungal infections |
| JP7346389B2 (ja) | 2017-09-13 | 2023-09-19 | ベー．エル．アー．ハー．エム．エス ゲゼルシャフト ミット ベシュレンクテル ハフツング | 異常な血小板レベルのマーカーとしてのプロアドレノメジュリン |
| EP3502706A1 (en) | 2017-12-20 | 2019-06-26 | B.R.A.H.M.S GmbH | Workflow for risk assessment and patient management using procalcitonin and midregional-proadrenomedullin |
| IL292863A (en) | 2019-11-13 | 2022-07-01 | Amunix Pharmaceuticals Inc | Barcoded xanthan polypeptides and their compositions, and methods for their preparation and use |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69332948T2 (de) * | 1992-03-05 | 2003-11-27 | Board Of Regents, The University Of Texas System | Verwendung von Immunokonjugate zur Diagnose und/oder Therapie der vaskularisierten Tumoren |
| WO1994025482A1 (en) | 1993-04-23 | 1994-11-10 | Evans Herbert J | Polypeptides that include conformation-constraining groups which flank a protein-protein interaction site |
| JP2774769B2 (ja) | 1993-04-26 | 1998-07-09 | 賢治 寒川 | アドレノメデュリン |
-
1996
- 1996-08-16 US US09/011,922 patent/US6320022B1/en not_active Expired - Lifetime
- 1996-08-16 AT AT96928205T patent/ATE180832T1/de not_active IP Right Cessation
- 1996-08-16 EP EP96928205A patent/EP0845036B1/en not_active Expired - Lifetime
- 1996-08-16 CA CA2229741A patent/CA2229741C/en not_active Expired - Fee Related
- 1996-08-16 WO PCT/US1996/013286 patent/WO1997007214A1/en not_active Ceased
- 1996-08-16 DE DE69602756T patent/DE69602756T2/de not_active Expired - Lifetime
- 1996-08-16 JP JP9509499A patent/JPH11512087A/ja not_active Withdrawn
-
2001
- 2001-08-16 US US09/931,700 patent/US7101548B2/en not_active Expired - Fee Related
-
2006
- 2006-09-05 US US11/517,599 patent/US7622272B2/en not_active Expired - Fee Related
- 2006-12-26 JP JP2006349430A patent/JP4077861B2/ja not_active Expired - Fee Related
-
2009
- 2009-09-29 US US12/569,821 patent/US7939639B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| AU6776596A (en) | 1997-03-12 |
| US20020055615A1 (en) | 2002-05-09 |
| US7101548B2 (en) | 2006-09-05 |
| US20100021469A1 (en) | 2010-01-28 |
| CA2229741A1 (en) | 1997-02-27 |
| JP4077861B2 (ja) | 2008-04-23 |
| US20070004630A1 (en) | 2007-01-04 |
| US7939639B2 (en) | 2011-05-10 |
| DE69602756D1 (de) | 1999-07-08 |
| WO1997007214A1 (en) | 1997-02-27 |
| US6320022B1 (en) | 2001-11-20 |
| JPH11512087A (ja) | 1999-10-19 |
| EP0845036B1 (en) | 1999-06-02 |
| EP0845036A1 (en) | 1998-06-03 |
| US7622272B2 (en) | 2009-11-24 |
| CA2229741C (en) | 2012-05-08 |
| DE69602756T2 (de) | 2000-02-10 |
| JP2007145850A (ja) | 2007-06-14 |
| AU710662B2 (en) | 1999-09-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE180832T1 (de) | Funktionelle rolle von adrenomedullin(am) und dem gen-verwandten produkt(pamp) in der menschlichen pathologie und physiologie | |
| Baluna et al. | Evidence for a structural motif in toxins and interleukin-2 that may be responsible for binding to endothelial cells and initiating vascular leak syndrome | |
| ATE267607T1 (de) | Verwendung von löslichen oligomerischen cd40 liganden oder monoklonalen antikörpern zur herstellung eines arzneimitells zur vorbeugung oder behandlung von neoplastischen krankheiten | |
| UA29494C2 (uk) | Гуманізовані антитіла, способи їх продукування, спосіб лікування хвороби крона, спосіб лікування розсіяного склерозу, фармацевтична композиція | |
| ES2227527T3 (es) | Un factor de crecimiento de queratinocitos (kgf) truncado que tiene actividad biologica aumentada. | |
| Bleuez et al. | Exploiting protease activation for therapy | |
| BRPI0413489A (pt) | composições polipeptìdicas de ligação a cd20 | |
| JP2011517319A5 (enExample) | ||
| RU94016384A (ru) | Лизосомные расщепляемые ферментами противоопухолевые лекарственные коньюгаты | |
| ATE332702T1 (de) | Verwendung von glu-trp dipeptiden zur herstellung eines arzneimittels zur behandlung von verschiedenen gefässneubildung-assozierten erkrankungen | |
| ATE306473T1 (de) | Neue piperazinyl-substituierte pyridylalkan, alken and alkin carboxamide | |
| HRP20020787B1 (hr) | Postupak liječenja upotrebom kompleksa ligand-imunogen | |
| NZ504549A (en) | Use of a modified non-toxic botulinum toxin for delivery of medicines where non-toxicity results from modification of light chain holotoxin to eliminate zinc-dependant metalloendoprotease without modification to the heavy chain portion essential for translocation activity from the gut to the lumen | |
| ATE342067T1 (de) | Verfahren zur behandlung von vaskulären proliferativen erkrankungen mit p27 und fusionen davon | |
| ES2074042T3 (es) | Exotoxina recombinante de pseudomonas construccion de una inmunotoxina activa con efectos secundarios menores. | |
| DE69310634D1 (de) | Verwendung von Taxol zur Herstellung eines Arzneimittels zur Behandlung von Krebs | |
| DE69425246D1 (de) | Monoklonale antikoerper gegen lfa-1 zur herstellung eines arzneimittels zur vorbeugung der transplantatabstossung von organen | |
| Stulc et al. | Inhibition of multifunctional dipeptidyl peptidase-IV: is there a risk of oncological and immunological adverse effects? | |
| DE59303365D1 (de) | Derivate in der vitamin d-reihe mit modifikationen in der 20 position, verfahren zu ihrer herstellung, zwischenprodukte für dieses verfahren, diese derivate enthaltende pharmazeutische präparate sowie deren verwendung zur herstellung von arzneimitteln | |
| WO1999016791A3 (en) | Compounds and methods for regulating cell adhesion | |
| Van Leuven et al. | Human pregnancy zone protein and alpha 2-macroglobulin. High-affinity binding of complexes to the same receptor on fibroblasts and characterization by monoclonal antibodies. | |
| TR199800717T2 (xx) | Amyotrofik lateral skleroz tedavisine y�nelik ila� haz�rlamak i�in | |
| DE59610251D1 (de) | Konjugat, umfassend einen wirkstoff, ein polypeptid und einen polyether | |
| NO922621L (no) | Farmasoeytiske preparater inneholdende antigen-antistoffkomplekser og anvendelser derav | |
| Rhodes | Resistance of tumour cells to macrophages: A short review |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |